The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study of early PET and biomarker dynamics in patients with stage 2 and 3 triple negative breast cancer treated with neoadjuvant response-adapted chemotherapy with pembrolizumab (NeoADAPT).
 
Phaedon D. Zavras
No Relationships to Disclose
 
Ruizhe Chen
No Relationships to Disclose
 
Hanfei Qi
No Relationships to Disclose
 
Lilja Solnes
Employment - Johns Hopkins Hospital
Honoraria - Molecular insights
Research Funding - Cellectar; Novartis; Precision Molecular Imaging
 
Jenna VanLiere Canzoniero
Stock and Other Ownership Interests - Rom Technologies Inc
Research Funding - Foundation Medicine; Personal Genome Diagnostics (PGDX)
Patents, Royalties, Other Intellectual Property - Patent pending through Johns Hopkins Technology Transfer office
 
Rita Denbow
No Relationships to Disclose
 
Sharon White
No Relationships to Disclose
 
Antonio C. Wolff
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Elizabeth M. Jaffee
Stock and Other Ownership Interests - ABMETA Therapeutics; Adventris
Consulting or Advisory Role - Achilles Therapeutics; Dragonfly Therapeutics; Medically Home; Mestag Therapeutics; NeoTX; NEUVOGEN; SURGE Therapeutics
Research Funding - Breast Cancer Research Foundation; Bristol-Myers Squibb; Lucence Diagnostics; Roche
Patents, Royalties, Other Intellectual Property - I developed GVAX which is being tested in the clinics. It was licensed to Adoro Biotech. IF it becomes commercial I will have the potential to receive royalties. Also, I have received milestone payments yearly.
Other Relationship - Break Through Cancer; CPRIT; Parker Institute; Parker Institute
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Abbvie; Athenex; Bristol-Myers Squibb; Calibr; Genomic Health; Halozyme; Merck; Pfizer; Pfizer; Polyphor; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Medimmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)